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ses). Results: Sixteen economic analyses were included; all studies used deci-
sion-tree structures to model acute prophylaxis, and 13 included a chronic-phase 
Markov module to capture long-term complications and recurrent VTE events. The 
model structures generally captured the important events needed to accurately 
estimate differences in costs and outcomes between different treatment strate-
gies. Eleven studies included rivaroxaban, 9 studies included dabigatran, 3 studies 
included apixaban, and no studies included edoxaban. The analyses that compared 
a NOAC with low molecular-weight heparin (LMWH) predominantly resulted in 
the NOAC dominating LMWH for patients with both THR and TKR. The results of 
analyses that compared NOACs with each other suggested that dabigatran is the 
least cost-effective option. There is limited evidence directly comparing rivaroxaban 
with apixaban, but our results suggested that rivaroxaban dominates apixaban for 
patients with TKR in the United Kingdom. ConClusions: Economic analyses of 
NOACs for primary VTE prophylaxis following THR and TKR surgeries show reason-
able consistency in the model structures used and events captured. The results 
strongly suggest that NOACs are cost-effective alternatives to LMWH. Dabigatran 
appears to be the least cost-effective NOAC. However, more research is needed to 
assess the cost-effectiveness of apixaban and edoxaban.
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objeCtives: Iron deficiency (ID) is highly prevalent in chronic heart failure (CHF) 
patients and imposes a significant disease burden for CHF patients with enormous 
impact on their outcome. Two pivotal studies (FAIR-HF and CONFIRM-HF) showed 
that the iron deficiency with ferric carboxymaltose (FCM), an i.v. iron, results in 
clinical meaningful benefits. The purpose of this study was to evaluate the cost-
effectiveness of FCM versus no-treatment and oral iron supplementation in CHF 
patients with iron deficiency w/o anemia. Methods: We developed a Cost-Utility-
Model to simulate disease progression in CHF patients using different strategies of 
iron deficiency management. Markov modelling techniques were used to estimate 
disease progression, based on health states, defined by NYHA classes and death. 
Monte Carlo simulation accounted for uncertainty. The model includes 5 states and 
monthly transitions. Probabilities were derived from clinical and epidemiological 
studies. The cohort definition was adapted from the FAIR-HF study. Direct costs 
(NYHA, inpatient, outpatient and iron treatment costs) from published sources were 
used and expressed in 2014 Euro from the payer’s perspective. QALYs and total costs 
were projected over a 4-year time horizon and discounted at 5% p.a. Results: 
Over a 4-year timeframe, costs and outcomes associated with FCM would amount 
to 18,797.39 € and 2.46 QALYs. Costs associated with oral treatment are 17,307.06 € 
and 2.37 QALYs (ICER per QUALY gained: € 16,921.62). Costs and outcomes associated 
with no-treatment are 17,934.15 € and 2.3 QALYs (ICER per QUALY gained: 5,411.23 € ). 
Due to a delayed disease progression in the FCM group NYHA costs are lower than 
with oral replacement and no-treatment. ConClusions: Iv iron treatment with 
FCM compared with oral iron in iron deficient CHF patients is clearly below the CE 
threshold of € 22.200-€ 33.300/QUALY typically used by the UK NICE and hence can 
be considered a cost efficient treatment strategy.
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objeCtives: Peripheral arterial disease entails increased mortality besides a sig-
nificant economic and humanistic burden, especially in patients with critical limb 
ischemia (CLI; stages III and IV). Prostanoids are usually indicated to those unsuit-
able for interventional therapy. We aimed to assess the overall costs of alprostadil 
(prostaglandin E1) as treatment for CLI compared with amputation from the per-
spective of the Instituto Mexicano del Seguro Social (IMSS). Methods: Based on 
published literature, information derived from an expert panel, and local official 
sources of unit costs and other parameters, we evaluated three categories of costs: 
acquisition and administration of alprostadil given 40µg twice a day for 28 days; 
surgery, hospital stay, and rehabilitation after amputation; incapacity, prosthesis, 
and pensions in assumed current workers. We conducted the analysis for a time 
frame of one year using a decision tree developed in Microsoft Excel®. We gathered 
the effectiveness of alprostadil from a clinical trial. All costs are expressed in 2014 
Mexican pesos (MXN). We performed a deterministic sensitivity analysis. Results: 
Excluding the prosthesis costs, total direct medical costs of alprostadil were MXN 
4006 (5.8%) lower than the direct medical costs expected with limb amputation 
(MXN 65,490 Vs. MXN 69,496). When costs due to incapacity, prosthesis, and pensions 
in the workforce subpopulation were included into the analysis, the net difference 
in favour of alprostadil reached MXN 8,864 (MXN 66,577 Vs. MXN 75,441) which is 
equivalent to an overall cost reduction of 11.8%. Deterministic sensitivity analysis 
showed the model is quite sensitive to the acquisition and intra-arterial costs of 
alprostadil. ConClusions: Acquisition and administration costs of alprostadil 
may be offset by the overall savings in direct medical costs and in payments due 
to incapacities and pensions.
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objeCtives: Determining pharmacoeconomic efficiency of actovegin in complex 
therapy of complicated chronic venous disease of lower extremities. Methods: 
old of £30,000. ConClusions: At a willingness-to-pay threshold of £20,000 per 
QALY, all NOACs are cost-effective compared with warfarin. There is considerable 
uncertainty between the different NOACs, but apixaban (5mg bd) had the highest 
expected incremental net benefit and the highest probability (60%) of being most 
cost-effective first line anticoagulant for the prevention of stroke in AF, primarily 
due to lower rates of intracranial haemorrhage, other clinically relevant bleeding, 
and myocardial infarction.
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objeCtives: To assess the cost-effectiveness of edoxaban versus acenocoumarol 
(VKA treatment) in the prevention of stroke and systemic embolic events in patients 
with non-valvular atrial fibrillation (NVAF) in Spain. Methods: A Markov model 
was developed and adapted to the Spanish setting to simulate the evolution of 
NVAF patients throughout their lifetime. The Cycle length was 1 month and differ-
ent health states such as stroke, bleeding and other cardiovascular complications 
were defined to mimic NVAF natural history. Drug’s safety and efficacy outcomes 
were obtained from the Phase III trial. The analysis was conducted from the Spanish 
National Health System (NHS) perspective. Edoxaban and acenocoumarol costs were 
calculated according to recommended doses. The costs of NVAF complications and 
disease management costs were obtained from available Spanish published sources. 
An annual discount of 3% for costs and health outcomes was applied. Results: 
Edoxaban resulted on average with 0.337 quality-adjusted life-years (QALYs) gained 
and 0.285 life years gained (LYG) compared with acenocoumarol. Due to the pro-
jected longer survival of patients, edoxaban could generate more costs per patient 
than acenocoumarol from the NHS perspective, but the incremental cost-effective-
ness ratio (ICER) for edoxaban was highly cost effective, at 7,888€ per LYG and 6,671 € 
per QALY gained. To evaluate study robustness subgroup analyses (such CHADS2> 3 
score and percentage of well controlled patients), and probabilistic sensitivity analy-
ses were performed. Those analyses confirmed the ICERs for edoxaban to be cost-
effective when applying the commonly accepted cost effectiveness threshold in 
Spain. ConClusions: Edoxaban is cost-effective compared with acenocoumarol 
from the NHS perspective in the prevention of stroke and systemic embolic events 
in patients with NVAF in Spain.
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objeCtives: Deep venous thrombosis (DVT) and pulmonary embolism (PE) com-
prise venous thromboembolism (VTE), the third most common cardiovascular ill-
ness after acute coronary syndrome and stroke and a raising public health concern 
due to its morbity and mortality and higher costs. Acute and long term treatments 
help to avoid complications. We assessed the costs and effectiveness of different 
regimens for treatment of DVT without PE under the perspective of the Mexican 
public health system. Methods: A seven-pathway decision tree allowed compari-
son of five competing strategies. Acute treatment for 7 days involved bemiparin 
115UI/Kg once daily (BEM), enoxaparin 1.5mg/Kg once daily (ENO-OAD), enoxaparin 
1.0 mg/Kg twice daily (ENO-BID), nadroparin 100UI/Kg twice daily (NAD) or unfrac-
tionated heparin administered as 80UI/Kg initial bolus followed by continuous 
infusion at a rate of 18/UI/Kg/hour (UFH). Long-term treatment consisted of daily 
doses of warfarin 5 mg given orally during 83 days (VKA). Direct medical costs 
included acquisition of medicines, care of further VTE episodes, and managing 
of adverse events/complications. Resource use was based on published literature 
and expert´s opinion. Local unit costs and diagnosis-related groups (DRG) costs 
were gathered. Effectiveness is expressed in terms of VTE-free patients and deaths 
avoided per 1000 treated. Deterministic and probabilistic sensitivity analyses were 
conducted. Results: Acute treatment with BEM was the most-effective interven-
tion with benefits ranging from 33 VTE-free patients and 7 deaths avoided (Vs. 
ENO-OAD and ENO-BID, respectively) to 64 VTE-free patients and 21 deaths avoided 
(both Vs. NAD) per 1,000 treated. BEM followed by warfarin was also the less costly 
regimen leading to overall cost-savings varying between MXN$3,067,626 (Vs. NFH) 
and MXN$7,084,142 (Vs. NAD) per 1,000 treated. Model results were robust to plau-
sible changes in main parameters. ConClusions: Bemiparin may present a cost 
saving alternative over the use of other low molecular weight heparins or UFH as 
initial therapy for patients affected by DVT without PE.
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objeCtives: The objectives of this systematic review were to identify published 
economic analyses of new oral anticoagulants (NOACs) for primary venous throm-
boembolism (VTE) prophylaxis following total hip replacement (THR) and total knee 
replacement (TKR) surgeries and to summarise the modelling techniques used and 
cost-effectiveness results. Methods: Electronic searches of MEDLINE, EconLit, and 
the Cochrane Library were performed from January 2008 to February 2015 using a 
combination of Medical Subject Headings and free-text terms that were grouped 
into the following categories: population (including terms for thromboembolism 
and orthopaedic surgery), intervention (including terms for apixaban, dabigatran, 
edoxaban, and rivaroxaban), and study design (including terms for economic analy-
